Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Expects PMA Supplement To Further Delay SOX Re-Launch

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific likely will submit data to FDA in the form of a premarket approval application supplement for the relaunch of the Nir-On-Ranger with SOX securement system, leading analysts to envisage a second-half 1999 return to market for the pre-mounted coronary stent system.

You may also be interested in...



Boston Scientific Settles With SEC On 1997/98 Japan Sales Irregularities

A settlement reached between Boston Scientific and the Securities and Exchange Commission in connection with improperly recorded sales by the company's Japanese operation does not include a fine.

Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?

While disappointing result will probably put an end to single-drug development plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.

UsernamePublicRestriction

Register

MT011386

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel